Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-03-01 Sale |
2023-03-02 5:01 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
1,684 | $76.36 | $128,594 | 94,066 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 5:00 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
1,923 | $76.36 | $146,845 | 131,666 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 4:55 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
2,198 | $76.36 | $167,845 | 135,676 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 4:51 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
755 | $76.36 | $57,654 | 87,132 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 4:49 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
2,164 | $76.36 | $165,248 | 220,628 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:24 pm |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
8,143 | $116.14 | $945,756 | 45,232 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:21 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
39,507 | $112.25 | $4,434,654 | 74,299 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:20 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
387 | $108 | $41,796 | 82,843 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:18 pm |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
212,500 | $108.74 | $23,106,230 | 13,622 (Direct) |
View |
| 2022-10-13 Sale |
2022-10-17 4:35 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $76.01 | $513,372 | 43,626 (Direct) |
View |
| 2022-10-06 Sale |
2022-10-07 4:16 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $84.37 | $569,835 | 50,380 (Direct) |
View |
| 2022-09-29 Sale |
2022-09-30 4:20 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $77.35 | $522,422 | 57,134 (Direct) |
View |
| 2022-09-22 Sale |
2022-09-26 4:19 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $77 | $520,058 | 63,888 (Direct) |
View |
| 2022-09-15 Sale |
2022-09-19 4:10 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
12,271 | $88.52 | $1,086,222 | 76,159 (Direct) |
View |
| 2022-09-08 Sale(A) |
2022-09-13 4:15 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
6,754 | $81.48 | $550,316 | 77,396 (Direct) |
View |
| 2022-09-09 Sale |
2022-09-12 4:32 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,863 | $88 | $163,944 | 84,150 (Direct) |
View |
| 2022-09-06 Sale |
2022-09-07 4:27 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,384 | $78.57 | $108,741 | 86,013 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:16 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
718 | $79.04 | $56,749 | 55,486 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:15 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
885 | $79.04 | $69,948 | 72,376 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:14 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
296 | $79.04 | $23,395 | 165,024 (Direct) |
View |
| 2022-09-02 Sale |
2022-09-06 5:12 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
269 | $79.04 | $21,261 | 83,230 (Direct) |
View |
| 2022-09-01 Sale |
2022-09-06 4:19 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
14,796 | $77.5 | $1,146,634 | 87,397 (Direct) |
View |
| 2022-08-03 Sale |
2022-08-04 4:32 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
5,959 | $73.73 | $439,328 | 28,672 (Direct) |
View |
| 2022-08-02 Sale |
2022-08-03 4:44 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
837 | $69.66 | $58,305 | 551,176 (Direct) |
View |
| 2022-08-02 Sale |
2022-08-03 4:44 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
437 | $69.66 | $30,441 | 34,631 (Direct) |
View |
| 2022-08-02 Sale |
2022-08-03 4:44 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
414 | $69.66 | $28,839 | 102,193 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-02-28 Option Award |
2023-03-02 5:01 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
18,621 | $0 | 94,066 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 5:01 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
30,971 | $76.97 | 94,066 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 5:00 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
19,055 | $0 | 131,666 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 5:00 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
31,691 | $76.97 | 131,666 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:58 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
12,992 | $0 | 77,885 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:58 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
21,607 | $76.97 | 77,885 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
17,755 | $0 | 64,438 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:56 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
29,531 | $76.97 | 64,438 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:55 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
23,818 | $0 | 135,676 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:55 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
39,614 | $76.97 | 135,676 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:51 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
12,125 | $0 | 87,132 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:51 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
20,168 | $76.97 | 87,132 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:49 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
21,653 | $0 | 220,628 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:49 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
36,013 | $76.97 | 220,628 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
150 | $62.3 | 17,152 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
66 | $62.3 | 74,442 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
102 | $62.3 | 165,126 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
98 | $62.3 | 28,770 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
108 | $62.3 | 55,594 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:24 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
1,946 | $0 | 45,232 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:24 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
1,946 | $47.04 | 45,232 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
7,500 | $11.46 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
35,209 | $0 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
7,826 | $14.37 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
5,517 | $7.15 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
7,183 | $21.15 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
25,000 | $11.46 | 13,622 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:18 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
212,500 | $0 | 13,622 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-09 6:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
39 | $62.3 | 13,622 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
187,500 | $7.15 | 13,622 (Direct) |
View |
| 2022-12-02 Exercise |
2022-12-05 4:33 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
2,000 | $7.15 | 82,128 (Direct) |
View |
| 2022-11-01 Option Award |
2022-11-03 4:42 pm |
2023-11-01 2032-10-31 |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
11,609 | $73.2 | 62,065 (Direct) |
View |
| 2022-11-01 Option Award |
2022-11-03 4:42 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,830 | $0 | 62,065 (Direct) |
View |
| 2022-09-15 Exercise |
2022-09-19 4:10 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
5,517 | $0 | 76,159 (Direct) |
View |
| 2022-09-15 Exercise |
2022-09-19 4:10 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
5,517 | $7.15 | 76,159 (Direct) |
View |
| 2022-08-02 Option Award |
2022-08-03 4:45 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
7,122 | $70.2 | 73,261 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:51 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
281 | $59.08 | 49,483 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:50 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
144 | $59.08 | 17,002 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:49 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
251 | $59.08 | 66,139 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:48 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
218 | $59.08 | 165,320 (Direct) |
View |